• 中药标准品生产商,产品定制服务
  • 地榆皂苷II

    Ziyuglycoside II

    地榆皂苷II
    产品编号 CFN98465
    CAS编号 35286-59-0
    分子式 = 分子量 C35H56O8 = 604.8
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Triterpenoids
    植物来源 The roots of Sanguisorba officinalis.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    地榆皂苷II CFN98465 35286-59-0 10mg QQ客服:3257982914
    地榆皂苷II CFN98465 35286-59-0 20mg QQ客服:3257982914
    地榆皂苷II CFN98465 35286-59-0 50mg QQ客服:3257982914
    地榆皂苷II CFN98465 35286-59-0 100mg QQ客服:3257982914
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Universidade da Beira Interior (Germany)
  • University of Queensland (Australia)
  • University of Medicine and Pharmacy (Romania)
  • Max Rubner-Institut (MRI) (Germany)
  • Seoul National University of Science and Technology (Korea)
  • Charles University in Prague (Czech Republic)
  • University of Madras (India)
  • Auburn University (USA)
  • University of Hertfordshire (United Kingdom)
  • Istanbul University (Turkey)
  • Utah State University (USA)
  • Uniwersytet Gdański (Poland)
  • University of Amsterdam (Netherlands)
  • Funda??o Universitária de Desenvolvimento (Brazil)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Phytochem Anal.2013, 24(5):493-503
  • Sci Rep.2015, 5:13194
  • FEBS Lett.2015, 589(1):182-7
  • Food Chem.2016, 191:81-90
  • Phytochem Anal.2016, 27(5):296-303
  • Chemistry of Plant Materials.2016, 33-46
  • J of the Korean Society of Food Science and Nutrition2016, 45(7):1017-1025
  • Food Analytical Methods2017, 10:3225–3234
  • J Bone Miner Res.2017, 32(12):2415-2430
  • J Nat Med.2017, 71(2):457-462
  • Journal of Analytical Chemistry2017, 854-861
  • PLoS One.2018, 13(4):e0195642
  • BMC Complement Altern Med.2018, 18(1):303
  • Mol Cells.2018, 41(8):771-780
  • J Herbmed Pharmacol.2018, 7(4):280-286
  • ACS Chem Biol.2019, 14(5):873-881
  • Molecules.2019, 24(1):E159
  • Chin J Pharm Anal.2019, 39(7):1217-1228
  • The Malaysian journal of pathology2019, 41(3):243-251
  • J Mol Histol.2019, 50(4):343-354
  • Appl Biol Chem2019, 62:46
  • Food and Chemical Toxicology2020, 111221
  • Biosci Biotechnol Biochem.2020, 84(3):621-632
  • ...
  • 生物活性
    Description: Ziyuglycoside II has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, it induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Ziyuglycoside II methyl ester possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes.
    Targets: ROS | JNK | p21 | Bcl-2/Bax | Caspase | p53
    In vitro:
    Toxicol Lett. 2014 May 16;227(1):65-73.
    Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.[Pubmed: 24680927]
    Ziyuglycoside II, a triterpenoid saponin compound extracted from Sanguisorba officinalis L., has been reported to have a wide range of clinical applications including anti-cancer effect. In this study, the anti-proliferative effect of ziyuglycoside II in two classic human breast cancer cell lines, MCF-7 and MDA-MB-231, was extensively investigated.
    METHODS AND RESULTS:
    Our study indicated that ziyuglycoside II could effectively induce G2/M phase arrest and apoptosis in both cell lines. Cell cycle blocking was associated with the down-regulation of Cdc25C, Cdc2, cyclin A and cyclin B1 as well as the up-regulation of p21/WAF1, phospho-Cdc25C and phospho-Cdc2. Ziyuglycoside II treatment also induced reactive oxygen species (ROS) production and apoptosis by activating the extrinsic/Fas/FasL pathway as well as the intrinsic/mitochondrial pathway. More importantly, the c-Jun NH2-terminal kinase (JNK), a downstream target of ROS, was found to be a critical mediator of ziyuglycoside II-induced cell apoptosis. Further knockdown of JNK by siRNA could inhibit ziyuglycoside II-mediated apoptosis with attenuating the up-regulation of Bax and Fas/FasL as well as the down-regulation of Bcl-2. Taken together, the cell death of breast cancer cells in response to ziyuglycoside II was dependent upon cell cycle arrest and cell apoptosis via a ROS-dependent JNK activation pathway.
    CONCLUSIONS:
    Our findings may significantly contribute to the understanding of the anti-proliferative effect of ziyuglycoside II, in particular to breast carcinoma and provide novel insights into the potential application of such compound in breast cancer therapy.
    In vivo:
    Nutrients. 2015 Jul 7;7(7):5469-83.
    Anti-Diabetic and Hepato-Renal Protective Effects of Ziyuglycoside II Methyl Ester in Type 2 Diabetic Mice.[Pubmed: 26198246]
    Type 2 diabetes is a metabolic disorder caused by abnormal carbohydrate metabolism, and closely associated with abnormal lipid metabolism and hepato-renal dysfunction. This study investigated the anti-diabetic and hepato-renal protective properties of ziyuglycoside I (ZG01) derivative on type 2 diabetes.
    METHODS AND RESULTS:
    ZG01 was isolated from roots of Sanguisorba officinalis and chemically modified by deglycosylation and esterification to obtained ziyuglycoside II methyl ester (ZG02-ME). Here, we showed that ZG02-ME has stronger anti-diabetic activity than the original compound (ZG01) through decreasing blood glucose, glycated hemoglobin (HbA1c), and insulin levels in a mouse model of type 2 diabetes (db/db mice). We further found that ZG02-ME treatment effectively ameliorated serum insulin, leptin and C-peptide levels, which are key metabolic hormones, in db/db mice. In addition, we showed that elevated basal blood lipid levels were decreased by ZG02-ME treatment in db/db mice. Furthermore, treatment of ZG02-ME significantly decreased serum AST, ALT, BUN, creatinine, and liver lipid peroxidation in db/db mice.
    CONCLUSIONS:
    These results demonstrated that compared to ZG01, chemically modified ZG02-ME possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.6534 mL 8.2672 mL 16.5344 mL 33.0688 mL 41.336 mL
    5 mM 0.3307 mL 1.6534 mL 3.3069 mL 6.6138 mL 8.2672 mL
    10 mM 0.1653 mL 0.8267 mL 1.6534 mL 3.3069 mL 4.1336 mL
    50 mM 0.0331 mL 0.1653 mL 0.3307 mL 0.6614 mL 0.8267 mL
    100 mM 0.0165 mL 0.0827 mL 0.1653 mL 0.3307 mL 0.4134 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    28-O-beta-D-吡喃葡萄糖果树酸酯; Pomolic acid 28-O-beta-D-glucopyranosyl ester CFN97328 83725-24-0 C36H58O9 = 634.9 5mg QQ客服:2159513211
    刺梨苷 F1; Kaji-ichigoside F1 CFN89311 95298-47-8 C36H58O10 = 650.85 5mg QQ客服:2159513211
    Rosamultin; Rosamultin CFN89097 88515-58-6 C36H58O10 = 650.85 10 mg QQ客服:2932563308
    苦莓苷F1; Niga-ichigoside F1 CFN91060 95262-48-9 C36H58O11 = 666.9 5mg QQ客服:1413575084
    山香醇酸糖苷F1; Suavissimoside F1 CFN91067 95645-51-5 C36H56O12 = 680.8 5mg QQ客服:2159513211
    地榆皂苷I; Ziyuglycoside I CFN98464 35286-58-9 C41H66O13 = 767.0 20mg QQ客服:2932563308
    3-氧代坡模酸; 3-Oxopomolic acid CFN92574 13849-90-6 C30H46O4 = 470.7 5mg QQ客服:3257982914
    3-氧代坡模酸甲酯; 3-Oxopomolic acid methyl ester CFN92820 14440-23-4 C31H48O4 = 484.7 5mg QQ客服:1148253675
    (3beta,6beta)-3,6,19-三羟基乌苏-12-烯-28-酸; Uncaric acid CFN99349 123135-05-7 C30H48O5 = 488.7 5mg QQ客服:2159513211
    6,19-二羟基乌苏-12-烯-3-氧代-28-酸; 6,19-Dihydroxyurs-12-en-3-oxo-28-oic acid CFN99892 194027-11-7 C30H46O5 = 486.7 5mg QQ客服:3257982914

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产